Search - tctmd.com

Displaying 41 - 60 of 62

Sort: Relevancy | Date

News Daily News

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Michael O'Riordan

June 09, 2016

News Conference News EAS 2016

Non-HDL Cholesterol, Inflammation Appear to Be Linked in Patients Undergoing Elective PCI

Yael L. Maxwell

June 08, 2016

News Conference News EAS 2016

Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts

Yael L. Maxwell

June 06, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Daily News

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Michael O'Riordan

April 02, 2016

News Daily News

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Michael O'Riordan

February 15, 2016

News Daily News

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Michael O'Riordan

February 15, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Michael O'Riordan

December 13, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

News Daily News

新型反义抑制剂能够降低高甘油三酯水平

August 13, 2015

News Daily News

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

August 13, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

Presentation SCCT 2015

Identifying Risk Beyond Stenosis in the ED Lessons Learned from ROMICAT

Presenter: Maros Ferencik

July 18, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Daily News

In-Stent Neoatherosclerosis Tied to Plaque Progression in Untreated Arteries

June 16, 2015

Advertisement

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Non-HDL Cholesterol, Inflammation Appear to Be Linked in Patients Undergoing Elective PCI

Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

新型反义抑制剂能够降低高甘油三酯水平

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Identifying Risk Beyond Stenosis in the ED Lessons Learned from ROMICAT

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

In-Stent Neoatherosclerosis Tied to Plaque Progression in Untreated Arteries

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content